Cefoxitin sodium
Based on 11 publication(s) in Google Scholar
Cefoxitin sodium (MK-306) is a cephalosporin-class antibiotic. Cefoxitin sodium is highly stable against β-Lactamase (HY-P2998). Cefoxitin sodium has a broad spectrum of antibacterial activity, including Gram-negative and Gram-positive bacteria.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.69%
- CAS No.: 33564-30-6
- Formule: C16H16N3NaO7S2
- Masse moléculaire:449.43
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Cefoxitin sodium
More- Nat Microbiol. 2023 Mar;8(3):410-423. [Abstract]
- Nat Commun. 2023 Mar 22;14(1):1594. [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- J Clin Microbiol. 2025 Aug 20:e0084125. [Abstract]
- Antimicrob Agents Chemother. 2025 May 23:e0024925. [Abstract]
- Microbiol Spectr. 2025 May 19:e0307424. [Abstract]
- J Antimicrob Chemother. 2025 Nov 5:dkaf408. [Abstract]
- J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. [Abstract]
- Infect Drug Resist. 2025 Oct 4:18:5239-5247. [Abstract]
- Diagn Microbiol Infect Dis. 2026 Feb;114(2):117181. [Abstract]
- bioRxiv. 2025 Jun 19.
Voir tous les produits spécifiques à Isoform Antibiotic
MoreVoir tous les produits spécifiques à Isoform Beta-lactamase
More
Activité biologique
Cefoxitin sodium (0-160 μM; 72 h) has MICs of 0.625 μM/mL (for strains CA8 and JLB31) and 1.25 μM/mL (for strain NP40) against three strains of B. burgdorferi[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Four-week-old female C3H/HeN mice[3]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection, daily, for five consecutive days
-
Result:Had shown high efficacy killing B. burgdorferi. B. burgdorferi was not detected in the tissue samples of the ears, urinary bladders, and hearts of the mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 33564-30-6
-
Appearance Solid
-
Masse moléculaire 449.43
-
Formule C16H16N3NaO7S2
-
Color White to light yellow
-
SMILES
O=C(C(N12)=C(COC(N)=O)CS[C@]2([H])[C@@](NC(CC3=CC=CS3)=O)(OC)C1=O)O[Na]
-
Synonyms
MK-306
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Microbiol
Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains. [Abstract]2023 Mar;8(3):410-423. PMID: 36759752 -
Nat Commun
2023 Mar 22;14(1):1594. PMID: 36949052 -
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
J Clin Microbiol
Luciferase reporter mycobacteriophage (TM4:: GeNL) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex. [Abstract]2025 Aug 20:e0084125. PMID: 40833127 -
Antimicrob Agents Chemother
An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]2025 May 23:e0024925. PMID: 40407337 -
Microbiol Spectr
Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]2025 May 19:e0307424. PMID: 40387379 -
J Antimicrob Chemother
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]2025 Nov 5:dkaf408. PMID: 41206063 -
J Antimicrob Chemother
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. [Abstract]2020 Jul 1;75(7):1850-1858. PMID: 32154866 -
Infect Drug Resist
In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline Against Mycobacterium abscessus. [Abstract]2025 Oct 4:18:5239-5247. PMID: 41069760 -
Diagn Microbiol Infect Dis
2026 Feb;114(2):117181. PMID: 41205476 -
Solvant et solubilité
DMSO : 100 mg/mL (222.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.56 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.56 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (111.25 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Cavalli Z, et al. Prolonged Cefoxitin Infusion Using Mobile Elastomeric Infusors In Outpatients With Bone And Joint Infection. J Bone Jt Infect. 2018 Sep 7;3(4):182-186. [Content Brief]
[2]. R N Brogden, et al. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979 Jan;17(1):1-37. [Content Brief]
[3]. Venkata Raveendra Pothineni, et al. In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease. Drug Des Devel Ther. 2018; 12: 2915–2921. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2250 mL | 11.1252 mL | 22.2504 mL | 55.6260 mL |
| 5 mM | 0.4450 mL | 2.2250 mL | 4.4501 mL | 11.1252 mL | |
| 10 mM | 0.2225 mL | 1.1125 mL | 2.2250 mL | 5.5626 mL | |
| 15 mM | 0.1483 mL | 0.7417 mL | 1.4834 mL | 3.7084 mL | |
| 20 mM | 0.1113 mL | 0.5563 mL | 1.1125 mL | 2.7813 mL | |
| 25 mM | 0.0890 mL | 0.4450 mL | 0.8900 mL | 2.2250 mL | |
| 30 mM | 0.0742 mL | 0.3708 mL | 0.7417 mL | 1.8542 mL | |
| 40 mM | 0.0556 mL | 0.2781 mL | 0.5563 mL | 1.3907 mL | |
| 50 mM | 0.0445 mL | 0.2225 mL | 0.4450 mL | 1.1125 mL | |
| 60 mM | 0.0371 mL | 0.1854 mL | 0.3708 mL | 0.9271 mL | |
| 80 mM | 0.0278 mL | 0.1391 mL | 0.2781 mL | 0.6953 mL | |
| 100 mM | 0.0223 mL | 0.1113 mL | 0.2225 mL | 0.5563 mL |
Powered by Bioz